Sernova (TSE:SVA) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sernova Corp., a clinical-stage biotech company, has announced the appointment of Jonathan Rigby to its Board of Directors. Rigby, with over three decades of biopharmaceutical experience and a personal connection to Type 1 diabetes, brings a wealth of industry knowledge from his previous leadership roles and board positions. His addition is expected to significantly contribute to Sernova’s mission to develop cell therapy treatments for chronic diseases, including a ‘functional cure’ for Type 1 diabetes.
For further insights into TSE:SVA stock, check out TipRanks’ Stock Analysis page.